文献速递浆细胞疾病造血干细胞移植与细胞治疗

Mezigdomide降解Ikaros减少T细胞功能障碍并提高抗骨髓瘤T细胞疗法疗效

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.
PubMed 文献 · Blood · 2026-01-01

本研究利用多发性骨髓瘤患者骨髓样本及原代T细胞模型,发现mezigdomide可显著减少表达TIGIT等耗竭标志物的功能障碍T细胞群。机制上,mezigdomide通过降解转录因子Ikaros,抑制其介导的耗竭基因TIGIT上调。体内实验还显示mezigdomide可增强抗BCMA CAR-T疗法的生存获益。

要点

  • Mezigdomide减少MM患者骨髓中表达TIGIT的耗竭T细胞。
  • Mezigdomide通过降解Ikaros下调TIGIT,改善T细胞功能。
  • Mezigdomide增强抗BCMA CAR-T体内生存获益。

核心结论

  • Mezigdomide通过降解Ikaros减少T细胞耗竭基因表达,改善抗骨髓瘤T细胞疗法疗效。

研究设计与样本

  • 使用多发性骨髓瘤患者骨髓样本及原代T细胞模型,结合多种表观遗传和转录组学技术及体内实验。

主要发现

  • Mezigdomide处理显著减少MM患者骨髓中表达TIGIT等耗竭标志物的功能障碍T细胞群。
  • Mezigdomide在原代T细胞功能障碍模型及双特异性TCE体外实验中改善T细胞功能和细胞毒性。
  • Mezigdomide通过降解Ikaros抑制TIGIT转录,减少T细胞耗竭。
  • 体内实验显示mezigdomide增强抗BCMA CAR-T疗法的生存获益。

临床怎么用

  • Mezigdomide有望与抗骨髓瘤CAR-T或TCE疗法联合,克服T细胞功能障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell dysfunction is an important contributor to both multiple myeloma (MM) disease progression and failure of antimyeloma chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (TCE) therapies. Overcoming T-cell dysfunction is therefore key to improving outcomes of patients with MM. Immunomodulatory drugs and cereblon E3 ligase modulatory drugs have been observed to activate T cells and, more recently, reduce T-cell dysfunction; however, the underlying mechanisms behind this are incompletely understood. Here, using bone marrow samples from patients with MM, we demonstrate a significant reduction in dysfunctional T-cell populations expressing exhaustion markers, such as TIGIT, upon treatment with mezigdomide. We further demonstrate the ability of mezigdomide to improve T-cell function and cytotoxicity in primary T-cell models of T-cell dysfunction and bispecific TCE therapy in vitro. Using concurrent assay for transposase-accessible chromatin using sequencing, chromatin immunoprecipitation sequencing, high-throughput chromatin conformation capture, and RNA sequencing in primary T cells treated with mezigdomide, we demonstrate the novel role of transcription factor Ikaros in regulating an important T-cell exhaustion gene TIGIT. Finally, we demonstrate the ability of mezigdomide to enhance survival outcomes of anti-B-cell maturation antigen CAR-T therapy in vivo. Overall, our data show that mezigdomide treatment improves antimyeloma T-cell therapy efficacy and reduces T-cell dysfunction by abrogating Ikaros-mediated upregulation of exhaustion genes.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chen LY, Aleman A, Larrayoz M, et al. Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies. Blood. 2026. PMID: 42101964. doi:10.1182/blood.2025030891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。